Please assess the completion status of the following clinical trial:

Trial Title: High-dose Chemotherapy With Autologous Stem Cell Transplantation in Poor Prognosis Germ-cell Tumors: TAXIF II

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Eligibility requirements includes the following criteria:~* Age \>18 years and \< 65~* Performance status \< 3~* Histologically or biologically documented GCTs~* Testicular, abdominal, or mediastinal tumors~* Measurable or evaluable disease~* Life expectancy \> 3 months~* Normal cardiac, liver, and renal function tests~* Absence of infection~* HIV negative test~* Signed informed consent~* All patients had to have been previously treated with at least one line of a cisplatin-containing regimen and were included if they were refractory after one or two line(s) of cisplatin-based CT, or had relapsed after two lines of a cisplatin-based CT~Exclusion Criteria:~* Fireproof diseases (progress unless month with regard to the last cycle of chemotherapy or in the course of chemotherapy)~* Relapses after complete answer obtained by surgery ( sCR )~* Neuropathy of superior rank or = II - renal Function (Office) superior creatinine or = 125 mmol/l and/or clearance of the creatinine subordinate or = II 60ml / mn~* Antecedents of congestive even compensated cardiac insufficiency~* Hurts of growing teratoma that is measurable hurts increasing by size (cutting) in the absence of rise of marker pens~* Extensive chemotherapy with support of haematopoietic stem cells. NB: A previous preventive irradiation under diaphragmatitis for a seminoma stage I (dose from 24 to 30 Gy in classic spreading) does not establish one against formal indication. However, an estimation clarifies capacities of the haematopoietic marrow is recommended with observation of the evolution of the NFP in the course of chemotherapy and quantification of cells CD 34 + in the peripheral blood. It's the same of the case where a chemotherapy by carboplatine was realized

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 1

Based on this trial design, predict the completion outcome and termination type (if applicable).